ERBB2 and breast carcinoma: D’Alesio et al. [80] explored the potential association of trastuzumab, a monoclonal antibody used for breast cancer therapy, and carnosic acid (14) on cell survival of ERBB2 over-expressing (ERBB2+) cells and whether compound 14 is able to restore trastuzumab sensitivity in cancer cells that have become resistant to the drug.